Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Reexamination Certificate
2004-07-07
2009-10-27
Jones, D L (Department: 1618)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
C424S001110, C424S001650, C424S009600
Reexamination Certificate
active
07608243
ABSTRACT:
The invention relates to new peptide-based compounds and their use in diagnostic optical imaging. More specifically the invention relates to the use of such peptide-based compounds as targeting vectors that bind to receptors associated with angiogenesis. The compounds are labeled with fluorescein and may be used as contrast agents in optical imaging in diagnosis of angiogenesis-related diseases.
REFERENCES:
patent: 7351790 (2008-04-01), Cuthbertson et al.
patent: 7368474 (2008-05-01), Cuthbertson et al.
patent: 7410943 (2008-08-01), Cuthbertson et al.
patent: 7521419 (2009-04-01), Cuthbertson et al.
patent: 2002/0102217 (2002-08-01), Hellebust et al.
patent: 01/77145 (2001-10-01), None
patent: 02/26776 (2002-04-01), None
Katada, et.al., “A Novel Motif for Platelet Fibrinogen Receptor Recognition” The Journal of Biological Chemistry, vol. 272, No. 12, Mar. 21, 1997, pp. 7720-7726.
Reicke, B., et.al. “Topical Application of Integrin Antagonists Inhibits Proliferative Retinopathy” Hormone and Metabolic Research, vol. 33, No. 5, May 2001, pp. 307-311.
De Groot F.M.H., et.al., “Design, Synthesis, and Biological Evaluation of a Dual Tumor-Specific Motive Containing Integrin-Targeted Plasmin-Cleavable Doxorubicin Prodrug” Molecular Cancer Therapeutics, American Assoc. of Cancer Research, US, vol. 1, Sept. 2002, pp. 901-911.
Int'l Search Report PCT/NO2004/000208 dated Dec. 2004.
Int'l Preliminary Exam report PCT/NO2004/000208 dated Sep. 2005.
Cuthbertson Alan
Indrevoll Bard
Solbakken Magne
Bohlken Craig
GE Healthcare AS
Jones D L
LandOfFree
Fluorescein-labelled peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fluorescein-labelled peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fluorescein-labelled peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4133126